Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
INmune Bio Inc. - Common stock
(NQ:
INMB
)
1.650
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about INmune Bio Inc. - Common stock
< Previous
1
2
3
4
Next >
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™
October 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Attend the 2026 Maxim Growth Summit
October 06, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
September 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
September 09, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
August 26, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
July 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
July 20, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
July 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 09, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 01, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
June 23, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
June 02, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
May 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
May 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
May 13, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
May 05, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
April 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
April 16, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
March 24, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
March 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
February 23, 2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
February 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
February 12, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
February 10, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
January 27, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 05, 2025
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
December 01, 2025
From
INmune Bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
